GlassScriptPhysician profile
Scott B Buchowski
NPI 1790170629
$17,407.61
in general payments reported to CMS, 2019-2025
27 companies · $13K in 2025
The $13K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.99 · 2020: $104 · 2021: $601 · 2022: $366 · 2023: $770 · 2024: $2,285 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $2,657 · Consulting Fee: $1,300 · Travel and Lodging: $973 · Education: $388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,920.00 |
| Food and Beverage | $2,656.54 |
| Consulting Fee | $1,300.00 |
| Travel and Lodging | $972.83 |
| Education | $387.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $14,405.90 | 2020-2025 | Tavneos, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $565.10 | 2021-2025 | Farxiga, Lokelma, Brilinta |
| Otsuka America Pharmaceutical, INC. | $498.59 | 2020-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $267.76 | 2021-2024 | Acthar, Terlivaz |
| Alexion Pharmaceuticals, INC. | $227.90 | 2021-2025 | Soliris, Ultomiris |
| Akebia Therapeutics INC | $170.22 | 2020-2024 | Vafseo, Auryxia |
| Calliditas Therapeutics US INC. | $158.48 | 2022-2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.18 | 2022-2025 | Jardiance |
| Opko Pharmaceuticals, LLC | $126.86 | 2021-2024 | Rayaldee |
| Novo Nordisk INC | $119.95 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Mallinckrodt Enterprises LLC | $99.99 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $92.44 | 2022-2024 | |
| Scpharmaceuticals INC. | $80.36 | 2025 | |
| Genzyme Corporation | $68.89 | 2022-2025 | |
| Vifor Pharma, INC. | $68.28 | 2020-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $47.77 | 2025 | |
| Fresenius USA Marketing, INC. | $46.10 | 2021-2024 | Velphoro |
| Travere Therapeutics, INC. | $41.48 | 2021-2024 | |
| Ardelyx, INC. | $29.86 | 2024-2025 | Ibsrela |
| Aurinia Pharma U.S., INC. | $21.59 | 2023 | Lupkynis |
| Glaxosmithkline, LLC. | $20.35 | 2022 | |
| Genentech USA, INC. | $19.75 | 2021 | |
| Horizon Therapeutics Plc | $16.81 | 2021 | |
| Pharmacosmos Therapeutics INC. | $16.53 | 2025 | Monoferric |
| Lilly USA, LLC | $16.32 | 2024 | Jardiance |
| Cycle Pharmaceuticals INC | $15.67 | 2025 | Venxxiva |
| Daiichi Sankyo INC. | $15.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Buchowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.